The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameShenzhen Chipscreen Biosciences Co Ltd
-
Registration countryChina
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









